Santiago Zelenay YOU? Author Swipe

Last 10y

DNGR-1 signalling limits dendritic cell activation for optimal antigen cross-presentation Open

Michael D. Buck, Tomas Castro‐Dopico, Oliver Schulz, Ana Cardoso, Probir Chakravarty , et al. · 2025

Innate immune receptors often induce activation of conventional dendritic cells (cDCs) and enhance antigen (cross-)presentation, favouring immune responses. DNGR-1 (CLEC9A), a receptor expressed by type 1 cDCs (cDC1s) and implicated in imm…

Corrigendum to RAS interaction with PI3K p110α is required for tumor-induced angiogenesis Open

Miguel Murillo, Santiago Zelenay, Emma Nye, Esther Castellano, François Lassailly , et al. · 2025

Supplementary File from MANIFEST: Multiomic Platform for Cancer Immunotherapy Open

Kok Haw Jonathan Lim, Zayd Tippu, Pippa Corrie, Michael Hubank, James Larkin , et al. · 2025

MANIFEST Consortium List of Authors

Data from MANIFEST: Multiomic Platform for Cancer Immunotherapy Open

Kok Haw Jonathan Lim, Zayd Tippu, Pippa Corrie, Michael Hubank, James Larkin , et al. · 2025

Summary:Immunotherapy has revolutionized survival outcomes for many patients diagnosed with cancer. However, biomarkers that can reliably distinguish treatment responders from nonresponders, predict potential life-threatening and life-chan…

Supplementary Table 1 from MANIFEST: Multiomic Platform for Cancer Immunotherapy Open

Kok Haw Jonathan Lim, Zayd Tippu, Pippa Corrie, Michael Hubank, James Larkin , et al. · 2025

Notable large-scale immuno-oncology consortia formed in the recent era.

CCR7+ Activated Dendritic Cells are Essential For Natural and Immunotherapy-Driven Anti-Tumor Immunity Open

Maria Koufaki, Eduardo Bonavita, Erin Richardson, Agrin Moeini, Massimo Russo , et al. · 2025

40P MANIFEST: A multiomic profiling platform for immuno-oncology biomarker discovery Open

Zayd Tippu, Kok Haw Jonathan Lim, Michael Hubank, Santiago Zelenay, Trevor D. Lawley , et al. · 2024

Vitamin D regulates microbiome-dependent cancer immunity Open

Evangelos Giampazolias, Mariana Pereira da Costa, Khiem C. Lam, Kok Haw Jonathan Lim, Ana Cardoso , et al. · 2024

A role for vitamin D in immune modulation and in cancer has been suggested. In this work, we report that mice with increased availability of vitamin D display greater immune-dependent resistance to transplantable cancers and augmented resp…

1254 Topical corticosteroids stimulate T cell-dependent melanoma growth control Open

C. Earnshaw, A. Moeini, Seok Theng Chiang, E. Bonavita, M. Koufaki , et al. · 2023

Supplementary Data from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy Open

Victoria S. Pelly, Agrin Moeini, Lisanne M. Roelofsen, Eduardo Bonavita, Charlotte R. Bell , et al. · 2023

Supplementary Figures and supplementary Methods

Table S7 from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy Open

Victoria S. Pelly, Agrin Moeini, Lisanne M. Roelofsen, Eduardo Bonavita, Charlotte R. Bell , et al. · 2023

Table S7

Table S2 from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy Open

Victoria S. Pelly, Agrin Moeini, Lisanne M. Roelofsen, Eduardo Bonavita, Charlotte R. Bell , et al. · 2023

Table S2

Table S6 from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy Open

Victoria S. Pelly, Agrin Moeini, Lisanne M. Roelofsen, Eduardo Bonavita, Charlotte R. Bell , et al. · 2023

Table S6

Table S1 from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy Open

Victoria S. Pelly, Agrin Moeini, Lisanne M. Roelofsen, Eduardo Bonavita, Charlotte R. Bell , et al. · 2023

Table S1

Data from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy Open

Victoria S. Pelly, Agrin Moeini, Lisanne M. Roelofsen, Eduardo Bonavita, Charlotte R. Bell , et al. · 2023

Identifying strategies to improve the efficacy of immune checkpoint blockade (ICB) remains a major clinical need. Here, we show that therapeutically targeting the COX2/PGE₂/EP2-4 pathway with widely used nonsteroidal and steroid…

Table S2 from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy Open

Victoria S. Pelly, Agrin Moeini, Lisanne M. Roelofsen, Eduardo Bonavita, Charlotte R. Bell , et al. · 2023

Table S2

Table S4 from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy Open

Victoria S. Pelly, Agrin Moeini, Lisanne M. Roelofsen, Eduardo Bonavita, Charlotte R. Bell , et al. · 2023

Table S4

Table S1 from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy Open

Victoria S. Pelly, Agrin Moeini, Lisanne M. Roelofsen, Eduardo Bonavita, Charlotte R. Bell , et al. · 2023

Table S1

Data from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy Open

Victoria S. Pelly, Agrin Moeini, Lisanne M. Roelofsen, Eduardo Bonavita, Charlotte R. Bell , et al. · 2023

Identifying strategies to improve the efficacy of immune checkpoint blockade (ICB) remains a major clinical need. Here, we show that therapeutically targeting the COX2/PGE₂/EP2-4 pathway with widely used nonsteroidal and steroid…

Table S6 from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy Open

Victoria S. Pelly, Agrin Moeini, Lisanne M. Roelofsen, Eduardo Bonavita, Charlotte R. Bell , et al. · 2023

Table S6

Table S7 from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy Open

Victoria S. Pelly, Agrin Moeini, Lisanne M. Roelofsen, Eduardo Bonavita, Charlotte R. Bell , et al. · 2023

Table S7

Table S3 from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy Open

Victoria S. Pelly, Agrin Moeini, Lisanne M. Roelofsen, Eduardo Bonavita, Charlotte R. Bell , et al. · 2023

Table S3

Table S5 from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy Open

Victoria S. Pelly, Agrin Moeini, Lisanne M. Roelofsen, Eduardo Bonavita, Charlotte R. Bell , et al. · 2023

Table S5

Table S3 from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy Open

Victoria S. Pelly, Agrin Moeini, Lisanne M. Roelofsen, Eduardo Bonavita, Charlotte R. Bell , et al. · 2023

Table S3

Supplementary Data from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy Open

Victoria S. Pelly, Agrin Moeini, Lisanne M. Roelofsen, Eduardo Bonavita, Charlotte R. Bell , et al. · 2023

Supplementary Figures and supplementary Methods

Table S5 from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy Open

Victoria S. Pelly, Agrin Moeini, Lisanne M. Roelofsen, Eduardo Bonavita, Charlotte R. Bell , et al. · 2023

Table S5

Table S4 from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy Open

Victoria S. Pelly, Agrin Moeini, Lisanne M. Roelofsen, Eduardo Bonavita, Charlotte R. Bell , et al. · 2023

Table S4

NKG2D Fine-Tunes the Local Inflammatory Response in Colorectal Cancer Open

Sophie Curio, Wanzun Lin, Christian P. Bromley, Jenny L. McGovern, Chiara Triulzi , et al. · 2023

Treating colorectal cancer (CRC) is a major challenge due to the heterogeneous immunological, clinical and pathological landscapes. Immunotherapy has so far only proven effective in a very limited subgroup of CRC patients. To better define…

COX-2 upregulation by tumour cells post-chemotherapy fuels the immune evasive dark side of cancer inflammation Open

Charlotte R. Bell, Santiago Zelenay · 2022

Cytotoxic therapies, such as chemotherapy and radiotherapy, are mainstays of cancer treatment for both early and unresectable, advanced disease. In addition to debulking the tumour mass through direct killing of pro-liferating tumour cells…

RNA sensing via LGP2 is essential for the induction of a type I IFN response in ADAR1 deficiency Open

Jorn E. Stok, Timo Oosenbrug, Laurens R. ter Haar, Dennis Gravekamp, Christian P. Bromley , et al. · 2021

RNA editing by the enzyme Adenosine Deaminase Acting on RNA 1 (ADAR1) is an important mechanism by which cells avoid innate immune responses to some endogenous RNAs. In ADAR1-deficient cells, unedited self RNAs can form base-paired structu…

Fetching topic information...